Posted by Michael Wonder on 06 Aug 2020
Darolutamide in prostate cancer: indication of considerable added benefit
3 August 2020 - Advantages in overall survival, symptoms and health-related quality of life.
Up to now, adult men with non-metastatic castration-resistant prostate cancer at high risk of developing metastatic disease usually continued their conventional androgen deprivation therapy while the cancer was observed for the occurrence of metastases (so-called watchful waiting).
The German Institute for Quality and Efficiency in Health Care has examined in an early benefit assessment whether adding the drug darolutamide offers an added benefit for patients in comparison with the appropriate comparator therapy.
Since the advantages in overall survival, symptoms and late complications, as well as in health-related quality of life are not accompanied by disadvantages, there is an indication of considerable added benefit.
